Business Wire

CORRECTING and REPLACING PHOTO Zynga Celebrates Bugatti’s 110th Anniversary with Special CSR Racing 2 Event Series

4.12.2019 20:27:00 EET | Business Wire | Press release

Share

Please replace the photo with the accompanying corrected photo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005025/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Zynga Celebrates Bugatti’s 110th Anniversary with Special CSR Racing 2 Event Series (Photo: Business Wire)

The release reads:

ZYNGA CELEBRATES BUGATTI’S 110TH ANNIVERSARY WITH SPECIAL CSR RACING 2 EVENT SERIES

Players Can Race and Collect Exclusive Bugatti-Engineered Hyper Sports Cars in Game

Today, Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, is launching an event series in partnership with the hyper sports car manufacturer Bugatti in the hit mobile drag racing game, CSR Racing 2 (CSR2). The event series, which celebrates Bugatti’s 110th anniversary, will give players the opportunity to collect and compete with the world’s most powerful and exclusive hyper sports cars in CSR2.

“Bugatti is one of the most iconic and revered car manufacturers in the world, and we are truly honored to celebrate such an important milestone with them,” said Julian Widdows, Vice President of CSR2. “Our team worked tirelessly to make sure everything from the cars’ sleek forms to their powerful engines is authentically represented in the game. This is the closest an aficionado can come to owning a Bugatti without actually buying one.”

The series showcases 24 different Bugatti cars, three of which are available exclusively in CSR2. Players can view the cars in augmented reality, giving them the experience of sitting in the driver’s seats of the most desirable hyper sports cars ever designed. The integration has seven different events over an eight-week period, and will be highlighted in a continued beta version of CSR2’s new player-versus-player feature, Showdown.

CSR2 Bugatti Exclusives:

  • Chiron Super Sport 300: the first series production car to break the magical 300 miles per hour barrier
  • La Voiture Noire: a one-off one grand tourisme masterpiece
  • Centodieci: the newly released homage to the original modern-day super sports car, EB110

“Interactive entertainment is a main driver for today’s young generation’s enthusiasm for cars and a great way to stay in touch with fans around the world,” said Bugatti President, Stephan Winkelmann. “We are very excited that through this partnership, our enthusiasts have the opportunity to experience all of our latest exclusive Bugatti hyper sports cars in CSR2.”

Every aspect of the 24 Bugatti cars, from the grills to the paint color, dashboard finish and stitching, has been meticulously recreated in CSR2 to mirror the real hyper sports cars. Players can explore the cars by tapping special points to trigger handcrafted, bespoke animations, allowing them to open doors, pop the hoods, inspect the engine bays, extend the spoilers and more.

CSR2 is available to download for free on the App Store as well as the Google Play Store. For more information about CSR2, visit the game’s community channels on Facebook, Twitter, Instagram, and YouTube.

Editor’s Note - To view the supporting assets for CSR Racing 2 (CSR2), please click here: https://app.box.com/s/56junq0iv8ibm2dx0mqfo8hpkd7qlk64

About Zynga Inc.

Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing™, Empires & Puzzles™, Merge Dragons!™, Words With Friends™ and Zynga Poker™. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter and Facebook.

About Bugatti

Bugatti Automobiles S.A.S. manufactures the world's most powerful, fastest, most exclusive and luxurious production hyper sports car. Since its foundation in 1909, the French luxury brand has been based on and off in Molsheim, Alsace. The Veyron was made there between 2005 and 2015, the first modern-day hyper sports car, of which 450 vehicles were built by hand. Since autumn 2016, the staff in Molsheim have been producing the Chiron1 models.

With an output of 1,500 hp, which has never before been achieved by production vehicles, a torque of 1,600 newton metres at 2,000 to 6,000 rpm and numerous technical innovations, the Chiron1 has been setting new standards in automotive engineering ever since.

In 2017, Bugatti delivered 70 vehicles to customers, by 2018 this had increased to 76. More than 80 vehicles are set to be delivered to customers in 2019. Bugatti has announced the construction of 500 models – currently only 100 Chiron can be ordered. Production of the Divo2, a vehicle optimised for lateral acceleration, will follow soon.

Bugatti has been part of the Volkswagen Group since 1998 and employs more than 300 people. The majority of these work in Molsheim in Alsace. With 37 dealers and service partners in 18 countries in Europe, North America, the Middle East and Asia-Pacific, Bugatti is a global player.

1 Fuel consumption, l/100km: urban 35.2 / extra-urban 15.2 / combined 22.5; combined CO2 emissions, g/km: 516; efficiency class: G

2 Fuel consumption, l/100km: not subject to Directive 1999/94/EC as overall type approval is currently not yet available

Forward Looking Statement

This press release contains forward-looking statements, relating to, among other things, the release of future CSR Racing 2 game features and events. Forward-looking statements often include words such as "outlook," "projected," “planned,” "intends," "will," "anticipate," "believe," "target," "expect," and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions are or will be described in greater detail in our public filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained by visiting our Investor Relations web site at http://investor.zynga.com or the SEC's web site at www.sec.gov

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Zynga Media Contact:
Kenny Johnston
kjohnston@zynga.com | (602) 999-1890

Or

Bugatti Automobiles S.A.S. Contact:
Tim Bravo
Head of Communications
Mobile: +33 640 151969
Email: tim.bravo@bugatti.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye